World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
45
Citations
9396
World Ranking
4975
National Ranking
1928

Overview

Gaston Picchio is affiliated with Johnson & Johnson in the United States and has contributed extensively to the field of medical research, with a strong focus on hepatitis viruses and liver disease. Their work spans various aspects of infectious diseases, especially hepatitis B and C viruses, and incorporates molecular biology, epidemiology, immunology, and antiviral therapies.

Picchio's research output includes numerous publications in high-impact journals. Notable papers include:

  • Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B (2022, Hepatology Communications)
  • Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells (2022, Journal of Hepatology)
  • Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity (2023, Hepatology Communications)
  • Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects (2022, Journal of Hepatology)
  • Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) (2022, Journal of Hepatology)

The scholar frequently publishes in the following venues:

  • Journal of Hepatology
  • Hepatology Communications
  • Antiviral Research
  • Journal of Antimicrobial Chemotherapy
  • Annals of Hepatology

Frequent coauthors include:

  • Emily P. Thi
  • Timothy Eley
  • Karen Sims
  • Michael J. Sofia
  • Edward Gane

Throughout their career, Picchio has focused on several key topics:

  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Viral gastroenteritis research and epidemiology
  • RNA Interference and Gene Delivery
  • Immunotherapy and Immune Responses
  • Immunodeficiency and Autoimmune Disorders

Their main fields of study center on Medicine, with subfields including Epidemiology, Hepatology, Infectious Diseases, Immunology, and Molecular Biology. This multidisciplinary approach supports an in-depth exploration of liver-related viral infections and immune system interactions.

Best Publications

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

    Hilde Azijn;Ilse Tirry;Johan Vingerhoets;Marie-Pierre de Béthune

  • Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection

    Vicky M.-H. Sung;Shigetaka Shimodaira;Alison L. Doughty;Gaston R. Picchio

  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

    Magali Bouvier-Alias;Keyur Patel;Harel Dahari;Stéphanie Beaucourt

  • Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo

    Pascal Poignard;Rebecca Sabbe;Gaston R Picchio;Meng Wang

  • Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

    Donald E. Mosier;Gastón R. Picchio;Richard J. Gulizia;Rebecca Sabbe

  • Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

    Christine Katlama;Richard Haubrich;Jacob Lalezari;Adriano Lazzarin

  • Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

    Johan Vingerhoets;Lotke Tambuyzer;Hilde Azijn;Annemie Hoogstoel

  • Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

    Graham R. Foster;Christophe Hézode;Jean–Pierre Bronowicki;Giampiero Carosi

  • Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

    Laurence Rimsky;Johan Vingerhoets;Veerle Van Eygen;Joseph Eron

  • Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

    James C. Sullivan;Sandra De Meyer;Doug J. Bartels;Inge Dierynck

  • Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

    Patrick Marcellin;Xavier Forns;Tobias Goeser;Peter Ferenci

  • hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis.

    Bruce E. Torbett;Gaston Picchio;Donald E. Mosier

  • Resistance profile of darunavir: combined 24-week results from the POWER trials.

    Unknown

  • Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

    Unknown

  • svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

    Ira M. Jacobson;Reem H. Ghalib;Maribel Rodriguez-torres;Zobair M. Younossi

  • Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

    Unknown

  • Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

    Tara L. Kieffer;Sandra De Meyer;Doug J. Bartels;James C. Sullivan

  • Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

    Unknown

  • Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

    Lotke Tambuyzer;Hilde Azijn;Laurence T Rimsky;Johan Vingerhoets

  • Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

    Unknown

  • Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES

    Cristina Pastore;Gastón R Picchio;Francesco Galimi;Richard Fish

  • Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy

    Pascal Veillon;Christopher Payan;Gastón Picchio;Michèle Maniez-Montreuil

  • The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

    Rima Kulkarni;Kerim Babaoglu;Eric B. Lansdon;Laurence Rimsky

  • Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

    Markus Cornberg;Anna Suk-Fong Lok;Norah A Terrault;Fabien Zoulim

Frequent Co-Authors

Donald E. Mosier
Donald E. Mosier Scripps Research Institute
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Pedro Cahn
Pedro Cahn University of Buenos Aires
Ira M. Jacobson
Ira M. Jacobson New York University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Bruce E. Torbett
Bruce E. Torbett Seattle Children's Hospital
Giampiero Carosi
Giampiero Carosi University of Brescia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens a variety of career paths, many of which intersect with health sciences and information management. For those interested in healthcare roles with a clinical focus, becoming a Functional Medicine Nurse Practitioner is a promising option, offering rewarding opportunities and competitive salaries. To learn more about this path, explore the functional medicine np salary insights.

Alternatively, if you have a knack for detail and coding, pursuing certification as a Professional Coder can lead to steady growth and valuable industry skills. The path to certification and expected earnings is detailed in the discussion about cpc.

Health Information Management (HIM) is another critical domain that combines healthcare with data management. A bachelor’s degree in this field enhances employability and earning potential, as noted in the overview of health information management bachelor degree salary.

For students seeking flexible learning options, numerous programs offer online HIM degrees accredited by CAHIIM. These accredited courses ensure quality training aligned with industry standards. Find top programs by checking the list of best online health information management degree cahiim accredited.

Best Scientists Citing Gaston Picchio

Trending Scientists